Liquidia (LQDA) Non Operating Income (2020 - 2026)
Liquidia (LQDA) posted Non Operating Income of -$3.8 million for Q2 2026, up 19.1% on a QoQ basis from -$4.7 million in Q1 2026, and up 6.23% year-over-year from -$3.6 million in Q2 2025.
Analysis
Liquidia (LQDA) Non Operating Income (2020 - 2026) Analysis & Trends
Liquidia has reported Non Operating Income for 7 years, with the latest figure at -$3.8 million in Q2 2026.
- On a quarterly basis, Non Operating Income rose 6.23% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$19.1 million, a 69.4% decrease from a year earlier, with the FY2025 full-year figure at -$17.5 million, down 150.79% from the prior year.
- Non Operating Income was -$3.8 million for Q2 2026 at Liquidia, up from -$4.7 million in the prior quarter.
- The five-year high for Non Operating Income was -$36000.0 in Q4 2022, with the low at -$5.3 million in Q3 2025.
- Average Non Operating Income over 5 years is -$2.2 million, with a median of -$1.7 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 82.09% in 2022, then tumbled 2716.67% in 2023.
- Over 5 years, Non Operating Income stood at -$36000.0 in 2022, then sank by 2716.67% to -$1.0 million in 2023, then tumbled by 136.98% to -$2.4 million in 2024, then slumped by 117.73% to -$5.2 million in 2025, then rose by 26.99% to -$3.8 million in 2026.
- The last three Non Operating Income figures came in at -$3.8 million (Q2 2026), -$4.7 million (Q1 2026), and -$5.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | - |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -139.24 Mn |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 41.90 Mn |
| 10 | Liquidia | 6.10 Bn | 5.81 Bn | 160.92 Mn | -3.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.82 Mn |
| Mar 31, 2026 | -4.72 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -5.30 Mn |
| Jun 30, 2025 | -4.07 Mn |
| Mar 31, 2025 | -2.94 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Sep 30, 2024 | -1.84 Mn |
| Jun 30, 2024 | -1.47 Mn |
| Mar 31, 2024 | -1.28 Mn |
| Dec 31, 2023 | -1.01 Mn |
| Sep 30, 2023 | -899,000.00 |
| Jun 30, 2023 | -692,000.00 |
| Mar 31, 2023 | -2.51 Mn |
| Dec 31, 2022 | -36,000.00 |
| Sep 30, 2022 | -261,000.00 |
| Jun 30, 2022 | -477,000.00 |
| Mar 31, 2022 | -1.47 Mn |
| Dec 31, 2021 | -201,000.00 |
| Sep 30, 2021 | -201,000.00 |